Australian company Immutep has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA. …
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News